27.04.2018 16:24:25
|
JSC Olainfarm Concludes Year 2017 With The Highest Turnover Of The Company's History And Expands Globally
April 27, 2018
JSC Olainfarm Concludes Year 2017 With The Highest Turnover Of The Company's History And Expands Globally
Audited consolidated financial statement of JSC Olainfarm for 2017 shows that the sales of the Group exceeded 122 million euros. This represents an increase by 10% compared to sales of 2016 and is by far the largest turnover in the company's history. The profit of Olainfarm Group last year reached 10.8 million euros.
The company has successfully expanded its export by adding new markets and selling its products now to 66 countries worldwide. Russia, Latvia, Ukraine and Belarus remain the largest product markets.
Together with the consolidated financial data, JSC Olainfarm this year also submitted for the first time a non-financial report, which informs about the company's environmental and social responsibility, quality management and corporate governance practice. The non-financial report is based on the Nasdaq ESG guidelines for the Nordic and Baltic markets.
Turnover growth was mostly ensured by the increase in sales of subsidiaries, as the sale of the Parent company in 2017 actually remained at the level of year 2016, increasing by a half percentage point.
The company has added 4 new markets to its product geography in 2017 and commenced sales in Argentina, Colombia, Hong Kong and Romania. In total, the Group exported its products to more than 60 countries worldwide.
In 2017, the share of Russia in total sales increased from 34% to 35%, while due to the changing economic situation, the sales in Ukraine decreased from 13% to 10%. Decline in sales volumes has been also experienced in Great Britain, while significant growth by 103% was reached in Germany, the Netherlands (+ 57%) and Belarus (+ 21%).
In 2017 JSC Olainfarm has successfully completed the registration of its products in Latvia, Kyrgyzstan, Armenia, Azerbaijan and Moldova. Registration processes are still ongoing in Nepal, Armenia, Turkey, Myanmar, Cameroon and Vietnam.
The best sold products of the Parent company in 2017 were CNS medicines Neiromidin, Noofen and Adaptol, antibacterial preparations of Furamag and Furasol, antiarrhythmic medicine Etacizin, antituberculosis products PASS Sodium salt and antiallergic medicine Fenkarol.
A slight change over the year has occurred in the proportion of the most sold products. The proportion of soluble Furagin products has increased from 13% to 15%, the share of Etacizin has increased from 8% to 10%, while the proportion of PASS Sodium Salt has decreased from 8% to 5%. The list of 10 the most-selling pharmaceutical products has remained unchanged.
The Annual meeting of shareholders of JSC Olainfarm on June 1, 2017 approved operating plan of the Group for 2017. According to it, sales of the Group in 2017 were planned to be 127 million euros, the parent company's turnover was expected to reach 96 million euros, while net profit - 15.5 million euros. Taking into account the unsatisfactory profitability in the third quarter, the company's board reviewed its 2017 earnings outlook, stating that the expected 2017 consolidated and non-consolidated profit is 9 million euros with potential to increase it to 10 million euros. According to the financial results of the consolidated financial statements, the Group's annual sales plan is executed at 96%, while the revised Group's annual profit plan is overflowing by 8%. The Parent company’s sales target is executed at 95%, while the profit plan is fulfilled by 93%.
Condensed Consolidated Statement of Financial Position | Group | Parent company | |||
31.12.2017 | 31.12.2016 | 31.12.2017 | 31.12.2016 | ||
EUR '000 | EUR '000 | EUR '000 | EUR '000 | ||
ASSETS | |||||
NON-CURRENT ASSETS | |||||
Intangible assets | 37 034 | 31 860 | 2 243 | 2 253 | |
Property, plant and equipment | 41 892 | 40 943 | 35 643 | 35 402 | |
Investment properties | 3 526 | 1 963 | 323 | - | |
Financial assets | 2 609 | 6 514 | 48 669 | 45 322 | |
TOTAL NON-CURRENT ASSETS | 85 061 | 81 280 | 86 878 | 82 977 | |
CURRENT ASSETS | |||||
Inventories | 24 161 | 24 011 | 17 551 | 17 447 | |
Receivables | 34 049 | 36 124 | 31 586 | 32 531 | |
Cash | 3 158 | 3 165 | 1 989 | 2 163 | |
TOTAL CURRENT ASSETS | 61 368 | 63 300 | 51 126 | 52 141 | |
TOTAL ASSETS | 146 429 | 144 580 | 138 004 | 135 118 | |
EQUITY AND LIABILITIES | |||||
EQUITY | |||||
Share capital | 19 719 | 19 719 | 19 719 | 19 719 | |
Share premium | 2 504 | 2 504 | 2 504 | 2 504 | |
Other components of equity | (74) | 322 | 40 | 322 | |
Retained earnings | 75 675 | 74 081 | 73 268 | 73 012 | |
Non-controlling interests | - | 37 | - | - | |
TOTAL EQUITY | 97 824 | 96 663 | 95 531 | 95 557 | |
LIABILITIES | |||||
Non-current liabilities | |||||
Borrowings | 15 878 | 18 800 | 14 805 | 17 777 | |
Deferred corporate income tax | - | 3 025 | - | 1 278 | |
Deferred income | 2 347 | 2 810 | 2 309 | 2 706 | |
Total Non-Current Liabilities | 18 225 | 24 635 | 17 114 | 21 761 | |
Current liabilities | |||||
Borrowings | 14 013 | 7 020 | 13 247 | 6 362 | |
Trade payables and other liabilities | 15 892 | 15 769 | 11 714 | 11 039 | |
Deferred income | 475 | 493 | 398 | 399 | |
Total Current Liabilities | 30 380 | 23 282 | 25 359 | 17 800 | |
TOTAL LIABILITIES | 48 605 | 47 917 | 42 473 | 39 561 | |
TOTAL EQUITY AND LIABILITIES | 146 429 | 144 580 | 138 004 | 135 118 |
Consolidated statement of comprehensive income | Group | Parent company | ||
2017 | 2016 | 2017 | 2016 | |
EUR '000 | EUR '000 | EUR '000 | EUR '000 | |
Net revenue | 122 076 | 110 693 | 91 713 | 91 096 |
Cost of goods sold | (47 231) | (40 855) | (30 441) | (29 678) |
Gross Profit | 74 845 | 69 838 | 61 272 | 61 418 |
Selling expense | (38 125) | (31 733) | (29 329) | (25 336) |
Administrative expense | (23 653) | (19 735) | (20 170) | (18 020) |
Other operating income | 2 697 | 3 080 | 2 342 | 2 363 |
Other operating expense | (4 427) | (9 766) | (4 564) | (10 675) |
Share of profit of an associate | 113 | 63 | - | - |
Income from investments in subsidiaries | - | - | 1 619 | 27 |
Financial income | 236 | 3 479 | 299 | 3 355 |
Financial expense | (2 299) | (307) | (1 930) | (285) |
Profit Before Tax | 9 387 | 14 919 | 9 539 | 12 847 |
Corporate income tax | (1 977) | (2 883) | (1 547) | (2 564) |
Deferred corporate income tax | 3 379 | (450) | 1 278 | (643) |
PROFIT FOR THE REPORTING PERIOD | 10 789 | 11 586 | 9 270 | 9 640 |
Other comprehensive loss for the reporting period | (114) | - | - | - |
Total comprehensive income for the reporting period | 10 675 | 11 586 | 9 270 | 9 640 |
Total comprehensive income attributable to: | ||||
The equity holders of the Parent Company | 10 675 | 11 579 | 9 270 | 9 640 |
Non-controlling interests | - | 7 | - | - |
Basic and diluted earnings per share, EUR | 0.77 | 0.82 | 0.66 | 0.68 |
JSC Olainfarm is one of the biggest pharmaceutical companies in Latvia with 45 years of experience in production of medication and chemical and pharmaceutical products. A basic principle of company's operations is to produce reliable and effective top quality products for Latvia and the rest of the world. Products made by the Group are being exported to more than 50 countries of the world, including the Baltics, Russia, other CIS, Europe, Asia, North America and Australia.
Information prepared by:
Salvis Lapins
JSC Olainfarm
Member of the Management Board
Rupnicu iela 5, Olaine, Latvia, LV 2114
Phone: +371 6 7013 717
Fax: +371 6 7013 777
E-mail: Salvis.Lapins@olainfarm.lv
Attachments
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Olainfarm A.S.mehr Nachrichten
Keine Nachrichten verfügbar. |